Navigation Links
HepaLife Announces Scientific Presentation of PBS-1 Cell Line at,International Influenza Meeting

BOSTON--(BUSINESS WIRE)--May 29, 2007 - HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) is pleased to announce a scientific presentation of its cell based PBS-1 technology for potential influenza vaccine production at the "Options for the Control of Influenza VI Conference," to be held June 17-23, 2007, in Toronto, Canada.

Entitled "High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases," and presented by K.A. Smith, from Michigan State University, the poster presentation will cover recent research results of the PBS-1 cell line and, among other things, challenges of current influenza vaccine production methodologies, which rely on embryonated chick eggs, and concerns over existing cell lines, which all require the addition of exogenous agents.

The single most important step towards the production of a cell-culture based vaccine against a targeted virus is the ability to grow the same virus in a cell substrate. In recent tests, the Company's patented 'PBS-1' cells, under development for influenza vaccine production, have successfully replicated numerous human influenza virus strains received from the Centers for Disease Control at substantially higher levels than the research community's widely-used current model, primary chick kidney cells.

Importantly, among the viruses successfully tested were three specific strains deemed currently most threatening by the World Health Organization and the U.S. Food and Drug Administration. These viruses were selected for development of the inactivated influenza vaccines prepared for the 2006-2007 influenza season.

In previous tests, the PBS-1 cells on average functioned five times better than primary chick kidney cells, and in some cases, outperformed them by 150-fold. Influenza viruses grown in PBS-1 cells are released into the culture fluid without the n
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/21/2014)... Md. , Nov. 21, 2014  The University ... will host the ceremonial groundbreaking of the new A. ... Park. The new building will cultivate transformative new engineering ... Taking place at 10:00 a.m. on November ... the Paint Branch Parking Lot, adjacent to the Jeong ...
(Date:11/21/2014)... Nov. 21, 2014   Rock Creek Pharmaceuticals, Inc., ... Company is scheduled to present at the Biotech Showcase™ ... on January 12-14, 2015. ... of Rock Creek Pharmaceuticals, will present preclinical and clinical ... which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline ...
(Date:11/21/2014)... 21, 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... Technology Award for Vision, Innovation, and Leadership has been awarded ... This award recognizes an individual who has had a significant ... for several decades. "I am honored ... Stuart Peltz , Ph.D., CEO of PTC Therapeutics, Inc. "When ...
Breaking Medicine Technology:University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3
... 16 , - Promising Efficacy ... Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) ... II studies evaluating,the efficacy, safety and tolerability of QVA149 at ... QVA149 is a novel once-daily,dry powder fixed dose bronchodilator combination ...
... , , ... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from ... 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...
Cached Medicine Technology:QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 2QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 3QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6
(Date:11/22/2014)... 2014 (HealthDay News) -- The wide variety and complexity ... threat for people with food allergies, an expert warns. ... many types of food allergies that it can be ... Dr. Guha Krishnaswamy, director of allergy and clinical immunology ... hospital news release. "If you know you have ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 This month has ... supplier, because it has received many positive reviews from some ... richness of its products by launching a new selection of ... time, global customers can enjoy free shipping and up to ... , Stylish ladies can always find the most suitable dress ...
(Date:11/22/2014)... November 22, 2014 Forbes Living ... are pleased to announce that Ashley Lombardo and friend ... contest. , Ms. Lombardo entered friend Candy Sherman ... She wrote of how her friend is courageously battling ... a single mom. Despite medical bills piling up and ...
(Date:11/22/2014)... 2014 A new technology for ... which safely detects and identifies hazards inside and ... Developed by RHT SpectraSafe, the technology avoids hazardous ... in other areas including medical, recycling, military, and ... high frequency radio waves that pass harmlessly through ...
(Date:11/22/2014)... OH (PRWEB) November 22, 2014 Wright ... for AndroGel side-effects lawsuits have been scheduled between ... Court, Northern District of Illinois. U.S. District Judge Matthew ... issued a Case Management Order (CMO) on November 6, ... deadlines for attorneys to submit documents and other activities ...
Breaking Medicine News(10 mins):Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 2Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 3Health News:First Bellwether Trials Scheduled In AndroGel Side-Effects Lawsuits Reports Wright & Schulte LLC 4
... Development, and Health at Harvard School of Public Health, has ... found that the disease costs a person $3.2 million over ... the new book Understanding Autism: From Basic Neuroscience to Treatment ... Autism,” Ganz says that autism costs $35 billion per year ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... of the Irish Medical Organization (IMO) has expressed his interest ... . Previously, Nora Owen, the party’s former Justice Minister held ... nomination in the Dublin North constituency and is positive about ... held on the 2nd of May. ,‘The people ...
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Researchers from the Simon Bolivar University in Caracas found ... the beans reduced its flatulence capacity// and increased the ... of nutrition especially in the developing countries. ... method of creating flatulence-free beans but not compromising on ...
... University suggests that men are more aware of potential rivals ... The researchers felt that men// become more jealous and wary ... their most fertile. ,The Evolution and Human Behaviour ... with ovulating partners were vary wary of the dominant looking ...
Cached Medicine News:Health News:The Price Of Autism 2Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2
... system continues the "Consensus Concept" approach ... with the diversified experience of a ... an affordable knee system that incorporates ... designed to provide both joint and ...
... The Optetrak system includes a cruciate ... Patellar flange mates with both resurfacing ... assure precise, repeatable kinematics and fit ... to reduce wear. Constant cutting guide ...
... result of more than a decade of ... on a comprehensive study of knee kinematics ... tibial insert retrieval analysis.,As a result of ... and motion patterns in total knees, the ...
... The Foundation® PS knee offers a femoral option ... cam action that engages at 60 degrees of ... motion and allow for 130 degrees of flexion. ... design with prominent lateral flare. The constrained tibial ...
Medicine Products: